HCLTech Signs an Exclusive Preferred Professional Services Agreement With Cloud Software Group for TIBCO Solutions
28.8.2023 16:04:00 EEST | Business Wire | Press release
HCLTech, a leading global technology company, announced an exclusive preferred professional services agreement with Cloud Software Group, to help implement, upgrade, modernize and provide services for all TIBCO products for enterprise customers across the globe. This partnership will help drive better value for end customers leveraging TIBCO products to further accelerate their data-driven digital transformation.
Cloud Software Group is the company formed upon completion of the Citrix take-private transaction and related combination with TIBCO. Today, Cloud Software Group provides the modern enterprise with mission-critical software through its key brands, including TIBCO, Citrix, NetScaler, Spotfire, XenServer, ShareFile, and Jaspersoft.
Cloud Software Group’s TIBCO customers will have access to enhanced digital transformation capabilities through HCLTech's technology offerings and consulting expertise across digital, cloud, automation, engineering and process optimization.
The addition of TIBCO products will further strengthen HCLTech’s professional services portfolio that already includes a comprehensive set of software product lines.
Close to 400 professional services employees from Cloud Software Group with expertise in TIBCO products will transition to HCLTech, bringing their deep domain knowledge to serve ongoing customer relationships and scale up HCLTech's existing TIBCO Center of Excellence.
“At Cloud Software Group, we’re constantly searching for opportunities to deliver an exceptional customer experience,” said Scott Harris, Senior Vice President, Cloud Software Group. “Through this partnership, we are enhancing and expanding how we support our TIBCO customers along their data journeys. With HCLTech’s long-standing history of expertise in innovation and cutting-edge digital technologies, we can further empower enterprises as they unlock the potential of real-time data through our platform.”
“This is a win-win partnership for both companies. We look forward to collaborating with Cloud Software Group’s product and support teams, adding yet another differentiator to our IT services portfolio,” said Anil Ganjoo, Chief Growth Officer, Americas, TMT and RCPG, HCLTech. “We look forward to an amazing journey with the new employees from Cloud Software Group and are thrilled to welcome them to HCLTech."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828017585/en/
Contact information
For further details, please contact:
HCLTech
Michelle Rico, Americas
michelle.rico@hcl.com
Elka Ghudial, EMEA
elka.ghudial@hcl.com
James Galvin, ANZ
james.galvin@hcl.com
Devneeta Pahuja, India and APAC
devneeta.p@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom